文/ 资本市场学院研究员 徐雅婷 ，中国人民大学深圳研究生院专职研究员 邢洋 为促进健全因地制宜发展新质生产力体制机制，支持构建同科技创新相适 应的科技金融体制，本文从产业金融供给、产业政策支持、产业生态构建 三个 维度对比 分析了 北 上 深津 常 以科 技金 融赋 能合 成生 物产 业发 展 的做 法，认为目前仍存在早期企业股权融资不足、银行信贷支持额小期短等问 题，建议下一步可在采取多维金融赋能方式、推动政策供给实施、完善产 业生态建设等方面支持合成生物产业发展。 习近平总书记强调，"要做好科技金融这篇文章，引导金融资本投早、投小、投长期、投硬科技"。《中共中央关于进一步全面深化改革、推进中国式现代 化的决定》提出要"建立未来产业投入增长机制"。目前，我国已初步建成了包括创业投资、银行信贷、保险、股票市场和债券市场等在内的多层次科技金 融服务体系，为新质生产力的形成与发展提供着强劲动力。然而，目前对科技金融赋能未来产业发展的逻辑和实践相关总结较为缺乏，本文基于合成生物 产业的特点，梳理科技金融赋能未来产业的逻辑与实践，在总结相关经验基础上提出政策建议。 科技金融赋能未来产业的逻辑 科技金融赋能未来产业的 ...

| 年第五次临时股东大会会议须知 3 2025 | | --- | | 2025 年第五次临时股东大会会议议程 5 | | 年第五次临时股东大会会议议案 7 2025 | | 《关于修订〈公司章程〉并办理工商变更登记的议案》 7 | | 《关于修订、制定公司部分治理制度的议案》 8 | | 《关于增加公司 2025 年度日常关联交易预计额度的议案》 10 | | 《关于使用部分超募资金永久补充流动资金的议案》 12 | 深圳华大智造科技股份有限公司 2025 年第五次临时股东大会会议资料 深圳华大智造科技股份有限公司 2025 年第五次临时股东大会 会议资料 2025 年 11 月 1 深圳华大智造科技股份有限公司 2025 年第五次临时股东大会会议资料 深圳华大智造科技股份有限公司 2025 年第五次临时股东大会会议须知 为保障深圳华大智造科技股份有限公司（以下简称"公司"）全体股东的合 法权益，维护股东大会的正常秩序，保证股东大会的议事效率，确保本次股东大 会如期、顺利召开，根据《中华人民共和国公司法》（以下简称《公司法》）、 《深圳华大智造科技股份有限公司章程》（以下简称《公司章程》）、《深圳华 大智造 ...

Core Insights - The integration of private venture capital, state-owned capital, and Hong Kong-Macau resources is creating a comprehensive capital network that supports the entire lifecycle of enterprises in the Guangdong-Hong Kong-Macau Greater Bay Area [1] - The Greater Bay Area is rapidly becoming a global hub for technological innovation and venture capital, driven by the collaboration of various capital sources [1] Group 1: Private Venture Capital - Private venture capital is a significant highlight in the Greater Bay Area, with firms like Dongfang Fuhai, Dacheng Caizhi, and others deeply engaged in the market [3] - The professional specialization among private venture capital firms is deepening, with specific focuses such as consumer sectors, hard technology, and precision medicine, enhancing investment accuracy and creating a collaborative ecosystem [3] - The success story of Ying Shi Innovation, which saw a 164% increase in R&D investment and a 90% rise in revenue, exemplifies the effective partnership between capital and technological innovation [2][3] Group 2: State-Owned Capital - State-owned venture capital plays a crucial role in the investment landscape, acting as a key funding source and shaping the investment framework in the Greater Bay Area [4] - The establishment of various funds, including a 150 billion yuan angel fund and a 500 billion yuan venture capital fund, demonstrates the commitment to fostering innovation and supporting emerging industries [4][5] - Shenzhen's state-owned capital has built a comprehensive innovation ecosystem, facilitating significant projects in the semiconductor industry and supporting early-stage investments through a network of seed funds [5][6] Group 3: Cross-Border Collaboration - Cross-border collaboration is being enhanced through institutional innovations, with many investment firms establishing connections between mainland China and Hong Kong to explore diverse investment opportunities [7][8] - The establishment of funds like the Qianhai Shenzhen-Hong Kong Youth Dream Factory Fund illustrates the growing trend of integrating resources and capital across borders to support early-stage projects in various sectors [7][8] - The unique conditions of the Greater Bay Area, characterized by "one country, two systems," present both challenges and opportunities for regional integration and development [8]

证券时报·数据宝统计，截至今日下午收盘，上证综指4029.50点，收于五日均线之上，涨跌幅0.73%，A 股总成交额为20656.81亿元。到目前为止，今日有1039只A股价格突破了五日均线，其中乖离率较大的 个股有天宏锂电、值得买、壹石通等，乖离率分别为19.95%、14.38%、10.30%；久立特材、文灿股 份、华大智造等个股乖离率较小，刚刚站上五日均线。 11月13日突破五日均线个股乖离率排名 （文章来源：证券时报网） | 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 五日均线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 920252 | 天宏锂 | 29.97 | 34.54 | 31.96 | 38.34 | 19.95 | | | 电 | | | | | | | 300785 | 值得买 | 20.00 | 21.80 | 35.36 | 40.44 | 14.38 | | 688733 | 壹石通 | 12.97 | 11.89 ...

Core Points - Shenzhen BGI Genomics Co., Ltd. announced a change in its continuous supervision sponsor representative [1] - CITIC Securities, the sponsor for the company's 2022 A-share IPO project, has replaced the original representative due to work adjustments [1] - The new sponsor representatives are Lu Ming and Wang Helin, ensuring the continuity of supervision duties [1] Summary by Sections - **Company Announcement** - The company confirms the authenticity and completeness of the announcement [2] - The board expresses gratitude to the outgoing representative for his contributions [1] - **Change of Sponsor Representative** - The original sponsor representative, Xiao Shaochun, is replaced by Wang Helin to maintain orderly supervision [1] - The continuous supervision period is set to last until December 31, 2025 [1]

Core Viewpoint - BGI Genomics announced a change in its sponsor representative for the ongoing supervision of its 2022 A-share IPO project, ensuring continuity in oversight responsibilities [1] Group 1 - CITIC Securities was appointed as the sponsor for BGI Genomics' 2022 A-share IPO project, with the supervision period lasting until December 31, 2025 [1] - The original sponsor representatives, Mr. Xiao Shaochun and Mr. Lu Ming, were responsible for the continuous supervision duties [1] - Mr. Xiao Shaochun will no longer be responsible for the supervision due to a work adjustment, and Mr. Wang Helin has been appointed to take over his responsibilities [1]

深圳华大智造科技股份有限公司 关于变更持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 深圳华大智造科技股份有限公司（以下简称"公司"）于近日收到中信证券 股份有限公司（以下简称"中信证券"）出具的《关于更换保荐代表人的函》。 中信证券作为公司 2022 年 A 股首次公开发行项目的保荐机构，原委派肖少春先 生和路明先生为保荐代表人履行持续督导职责，持续督导期至 2025 年 12 月 31 日止。 证券代码：688114 证券简称：华大智造 公告编号：2025-073 原保荐代表人肖少春先生现因工作调整，不再负责对公司的持续督导工作， 为保证持续督导工作的有序进行，中信证券现委派王贺麟先生（简历详见附件） 接替肖少春先生担任公司的保荐代表人，并继续履行持续督导的相关职责和义务。 本次变更后，公司 2022 年 A 股首次公开发行项目的保荐代表人为路明先生 和王贺麟先生。本次变更不影响中信证券对公司的持续督导工作，公司董事会对 肖少春先生在担任公司保荐代表人期间做出的贡献表示衷心感谢！ 特此公告。 王贺 ...

Core Viewpoint - The company reported its Q3 2025 earnings, achieving revenue of 1.869 billion yuan, which is essentially flat year-on-year, and a net profit attributable to shareholders of -120 million yuan, an improvement from -463 million yuan in the same period last year, indicating a reduction in losses and meeting prior expectations [1][2][3]. Financial Performance - For the first three quarters of 2025, the company achieved revenue of 1.869 billion yuan, with a net profit attributable to shareholders of -120 million yuan, compared to -463 million yuan in the previous year, and a non-recurring net profit of -228 million yuan, improving from -497 million yuan year-on-year [3][4]. - In Q3 2025, the company reported revenue of 755 million yuan, a year-on-year increase of 14.45%, driven by steady progress in domestic substitution and accelerated development in automation and multi-omics businesses [3][4]. - The company’s gross margin for the first three quarters was 53.32%, down 8.15 percentage points, primarily due to competitive pressures affecting product margins [8]. Business Segments - The full-read long sequencing business saw a steady increase in instrument sales, with the successful launch of the T7+ product, although instrument sales revenue slightly declined due to product mix effects [4]. - The smart automation business segment has been upgraded to focus on automation, with steady revenue growth in the first three quarters of 2025 [5]. Technological Advancements - The company is actively applying AI technologies in its smart automation business, enhancing its capabilities through new platforms and modules, which are expected to improve efficiency and reduce costs [5]. - A licensing agreement with SwissRockets for the CoolMPS sequencing technology is expected to generate at least 120 million USD in upfront payments and milestone payments, reflecting the company's technological leadership [6][7]. Future Outlook - The company is well-positioned to benefit from the domestic substitution trend, especially following the U.S. restrictions on Illumina, which may enhance its market share [9]. - The global sequencing industry is expected to see improved demand as macroeconomic conditions stabilize, with the company’s losses anticipated to narrow as operational efficiencies improve [9][10]. - Revenue projections for 2025-2027 are 3.041 billion, 3.389 billion, and 3.763 billion yuan, with net profits expected to improve significantly over the same period [10].

证券代码：688114 证券简称：华大智造 公告编号：2025-072 深圳华大智造科技股份有限公司 关于召开2025年第五次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 股东大会召开日期：2025年11月26日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络 投票系统 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第五次临时股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票 相结合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 11 月 26 日 15 点 00 分 召开地点：深圳市盐田区梅沙街道云华路 9 号华大时空中心 C 区国际会议 中心 419 会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 11 月 26 日 至2025 年 11 月 26 日 （六） 融资融券、转融通、约 ...

Core Viewpoint - Fujian Haichuang Optoelectronics Technology Co., Ltd. (referred to as "Haichuang Optoelectronics") has terminated its IPO application for the Sci-Tech Innovation Board, with the withdrawal being a mutual decision between the company and its sponsor, Industrial Securities Co., Ltd. [2] Business Segments Laser Radar Business - The company possesses core technologies for key components of automotive-grade laser radar and has independently developed a 1.5µm fiber laser radar light source module and a 905nm laser radar receiving module, achieving mass production and delivery [3] - Haichuang Optoelectronics is a major supplier of 1.5µm automotive laser radar components globally and has established partnerships with well-known companies such as Luminar and Innoviz [3] - The 1.5µm MOPA laser technology has applications in emerging markets like low-altitude economy and free-space optical communication, with orders from notable clients including DJI and Google [3] Industrial Laser Business - The company has advanced laser micro-optics technologies and stable partnerships with leading laser manufacturers, holding significant market share in niche markets [4] - It is a primary supplier of semiconductor laser components to various manufacturers, breaking the reliance on imports for certain products [4] Optical Communication Business - The company utilizes precision polishing and advanced optical film design to manufacture micro-communication optical components, enhancing broadband capacity and transmission rates [4] - Established collaborations with prominent clients in the optical communication sector, including Coherent and Source Photonics [4] Biomedical Sector - The company has developed endoscopic lenses and flow chamber products that meet international standards, contributing to the localization of high-end medical devices in China [5] - It has produced medical solid-state photomultiplier detectors that compete with foreign products, currently in the market introduction phase [5] Other Fields - In the semiconductor and aerospace sectors, the company has developed microscopes for wafer inspection, becoming the sole domestic supplier for a major client [5] - Its HUD products are used in domestic aircraft, contributing to national security by reducing reliance on foreign technology [5] Shareholders - The top ten shareholders of Haichuang Optoelectronics include Fuzhou Rongpu, Fuzhou Aopuda, and others, indicating a diverse ownership structure [6]